Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Matthew M Y Lee; Søren L Kristensen; Hertzel C Gerstein; John J V McMurray; Naveed Sattar

doi:10.1016/j.dsx.2021.102382

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Matthew M Y Lee, Søren L Kristensen, Hertzel C Gerstein, John J V McMurray, Naveed Sattar

Department of Cardiology

Abstract

BACKGROUND AND AIMS: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings.

METHODS: We meta-analysed its results with eight prior GLP-1 receptor agonists trials.

RESULTS: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81-0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83-0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials.

CONCLUSION: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650.

Original language	English
Article number	102382
Journal	Diabetes & metabolic syndrome
Volume	16
Issue number	1
ISSN	1871-4021
DOIs	https://doi.org/10.1016/j.dsx.2021.102382
Publication status	Published - Jan 2022

Keywords

Cardiovascular Diseases/etiology
Diabetes Mellitus, Type 2/drug therapy
Freedom
Glucagon-Like Peptide-1 Receptor/agonists
Humans
Hypoglycemic Agents/therapeutic use

Access to Document

10.1016/j.dsx.2021.102382

Cite this

@article{e51de905c63c48f9b6bba06a095fd162,

title = "Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial",

abstract = "BACKGROUND AND AIMS: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings.METHODS: We meta-analysed its results with eight prior GLP-1 receptor agonists trials.RESULTS: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81-0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83-0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials.CONCLUSION: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650.",

keywords = "Cardiovascular Diseases/etiology, Diabetes Mellitus, Type 2/drug therapy, Freedom, Glucagon-Like Peptide-1 Receptor/agonists, Humans, Hypoglycemic Agents/therapeutic use",

author = "Lee, {Matthew M Y} and Kristensen, {S{\o}ren L} and Gerstein, {Hertzel C} and McMurray, {John J V} and Naveed Sattar",

year = "2022",

month = jan,

doi = "10.1016/j.dsx.2021.102382",

language = "English",

volume = "16",

journal = "Diabetes & metabolic syndrome",

issn = "1871-4021",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes

T2 - A meta-analysis with the FREEDOM cardiovascular outcomes trial

AU - Lee, Matthew M Y

AU - Kristensen, Søren L

AU - Gerstein, Hertzel C

AU - McMurray, John J V

AU - Sattar, Naveed

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND AND AIMS: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings.METHODS: We meta-analysed its results with eight prior GLP-1 receptor agonists trials.RESULTS: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81-0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83-0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials.CONCLUSION: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650.

AB - BACKGROUND AND AIMS: FREEDOM, a cardiovascular outcome trial with a GLP-1 receptor agonist, testing a continuous subcutaneous infusion of exenatide (ITCA 650), recently reported its findings.METHODS: We meta-analysed its results with eight prior GLP-1 receptor agonists trials.RESULTS: GLP-1 receptor agonists reduced MACE by 13% (HR 0.87 [95% CI 0.81-0.94]; p = 0.00065) and all-cause mortality by 11% (HR 0.89 [0.83-0.95]; p = 0.00084). However, FREEDOM results appear dissimilar to prior GLP-1 receptor agonist trials.CONCLUSION: FREEDOM results should not influence current considerations about the benefits or harms of approved formulations of GLP-1 receptor agonists. There is also an ongoing debate about the safety of ITCA 650.

KW - Cardiovascular Diseases/etiology

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Freedom

KW - Glucagon-Like Peptide-1 Receptor/agonists

KW - Humans

KW - Hypoglycemic Agents/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85122589086&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2021.102382

DO - 10.1016/j.dsx.2021.102382

M3 - Review

C2 - 35030451

SN - 1871-4021

VL - 16

JO - Diabetes & metabolic syndrome

JF - Diabetes & metabolic syndrome

IS - 1

M1 - 102382

ER -

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this